The mechanism of action of the nuclear hormone receptors (NHRs) as generegulatory molecules has become a major focus of current biological interest. NHRs belong to the superfamily of ligand-activated transcription factors, which are involved in the regulation of homoeostasis, reproduction, development and differentiation. To fully understand their functions, it is important to know the functional three-dimensional structure of these proteins. Molecular cloning and structure-function analyses have revealed that NHRs commonly have three functional regions: the N-terminal, DNA-binding and ligand-binding domains. Structures of some of these domains expressed independently have been solved. However, to date the three-dimensional structure remains unknown for fulllength and even for any two domains together of any NHR family member. The available structures nevertheless begin to give clues of how site-specific DNA binding takes place, and how ligand binding alters the ligand-binding domain, consequently affecting potential interactions of the NHRs with co- activators/co-repressors and other components of basal transcriptional machinery. However, precisely how signals from a ligand through its NHR are passed to specific genes is still unknown. Herein, we present a broad overview of current knowledge on the structure and functions of the NHRs.
Introduction
The family of transcription factors known as nuclear hormone receptors (NHRs) was so named because many are ligand-activated, and thus mediate the biological effects of hormones or hormone-like substances. These include vitamin D 3 , thyroxin, retinoids, sex and adrenal steroids, and certain metabolic ligands such as certain fatty acids and oxysterols. Each ligand type binds to and thereby activates one or a closely related set of a few NHR isoforms. In this context, 'activation' refers to ligand-dependent alteration in the ability of the NHR to affect transcription. All members of the NHR family are recognizable due to similarities of certain modular domains, the closest link being provided by the DNA-binding domain (DBD). Including isoforms and depending on species, 100 or more receptor proteins with modular structures that classify them as NHRs may exist, forming the largest family of structurally related metazoan transcription factors, the nuclear receptor superfamily. Many NHRs remain orphan receptors; that is, they have no known ligands as yet. It seems clear now that many NHRs influence transcription in the absence of a ligand. In some cases, that influence is altered when its ligand binds the NHR. Other NHRs may regulate transcription without the requirement for a ligand. Each type of NHR acts to regulate expression of a set of specific genes related to metabolism, development or reproduction. By molecular genetics approaches, it was found that certain regions in the proteins of this group served particular functions, and that these regions could even be transferred among the family members, to make hybrid-function molecules. Thus the concept arose that these receptor proteins comprise semi-autonomous domains or modular structures. As more has been learned, it has become clear that there are limits to this domain concept, since domains may overlap, serve multiple functions and influence one another. Nevertheless, the basic presence and function of the primary domains remains undisputed.
Although the structural organization of NHRs into their three major functional domains, N-terminal transactivation domain (NTD), DBD and C-terminal, ligand-binding domain (LBD) is well characterized ( Figure 1A ), precisely how transcription is regulated by NHRs is unknown with any degree of rigor. The general outline of how NHRs regulate transcription is known, however. The unliganded receptor may be found in a steady state in both nuclear and cytoplasmic compartments. The proportion in each varies with receptor type, although most NHRs are to be found largely in the nuclear compartment, as the family name implies. For the ligand-activated group, activation frees the receptor to search for and bind with high affinity to specific DNA The DBD is the most conserved domain. Its globular structure is responsible for site-specific DNA binding at its response element and some important protein-protein interactions. The second most conserved domain, LBD, is a 12-13-helix globule responsible for ligand binding and aspects of homo-and/or hetero-dimerization. It contains a ligand-dependent transcriptional activation region (AF2). In some cases it may be in the active conformation without a ligand being bound. The diagram shown represents an active conformation. Among members of t he superfamily, the NTD is the least conserved, both in size and primary sequence. When present, the powerful transactivation region AF1 lies within this domain. This region is rich in acidic amino acids, and appears natively to be mostly unstructured. (B) A model for the regulation of transcription by NHR-cofactor assemblies. Both AF1 and AF2 regions recruit certain specific cofactors. A bridge is formed between AF1 and AF2 through these and/or other cofactor(s). AF1 and AF2 can also interact directly. The cofactor(s) bound are determined by their levels in particular cell types and by the state of the folded structures of the NHR. The complex alters local chromatin structure (red arrow), e.g. by catalysing histone acetylation or deacetylation, and affects the stabilization of the transcription pre-initiation complex [TATA-box-binding protein (TBP)-TBP-associated factors (TAFs)-RNA polymerase II (RNA Pol II)]. The receptor complex, bound to DNA enhancer sites, thus recruits and regulates polymerase II via accumulations of specific proteins (blue arrow), which make a functional bridge between the receptor and polymerase II. The activity of kinases and phosphatases regulating signalling pathways also contribute to this process by altering the state of phosphorylation of both receptor and cofactors (not shown). The receptor-cofactor assembly may also interact directly with the basal transcription machinery at the TBP/TATA box to regulate transcription. Different colours and shapes show the cofactor proteins. The question marks refer to factors, which may vary depending upon the cell type, ligand and promoter. Precise relationships and site of these cofactor proteins are not accurate and may differ in different NHRs. CBP, cAMP-response-element-binding protein (CREB)-binding protein; TFII, transcription factor II; DRIP/TRAP, vitamin D receptor-interacting protein/ thyroid receptor-associated protein; p/CIP, p300/CBP-interacting protein; SWI/SNF, switch/sucrose non-fermenting; SRC-1, steroid receptor co-activator 1. D R I P / T R A P sequences (response elements) and protein partners [1] . These presumably bind and release DNA non-specifically until the proper DNA sequence is reached, at which the higher affinity binding somehow controls transcription. At such specific 'response elements', co-operative binding of homo-or hetero-meric NHR dimers localizes the receptor and promotes further protein-protein interactions. These interactions are responsible for changes in transcription of the specific genes specified by the response element. Several mechanisms may be involved, each involving certain protein-protein contacts. The NHR may contact the large, multiprotein primary initiation complex directly, or may influence its functions indirectly, by binding a variety of proteins known as co-activators and co-repressors. These proteins may be able to bind members of the primary transcription complex and/or alter chromatin structure by acetylating or deacetylating histones in the neighbourhood of the cognate response element to which their tethering NHR is bound ( Figure 1B ). So far as it goes, this model serves well, but it fails to explain explicitly how the relatively small number of different NHRs can achieve the high level of specificity required to regulate the complex pattern of genes affected by NHRs. At present, the general assumption is that the complexes involving various cofactor proteins must do so.
The ability of a small molecule (ligand) to switch each ligand-activatable NHR from its inactive to its active form, thereby causing it to carry signals to regulate specific genes, has facilitated biochemical and biophysical approaches tremendously towards elucidating the mechanism of action of NHRs. Several new discoveries in recent years have added new excitement to the study of NHR function. Among these, the discovery that specific ligands can act as agonists or antagonists to varying degrees in different tissues has completely changed the thinking about how ligands and NHRs function. Structural knowledge of some NHR domains has only begun to explain this phenomenon. Thus, while the general mechanism of how NHRs regulate transcription (discussed above), is useful, it fails to explain several important facts. How do specific ligands within a class act to cause differing NHR functions in various tissues? How do NHRs pass the message from ligand to gene? Why do NHRs possess more than one transactivation region, and what causes these regions often to work in a synergistic manner? What are kinetics of NHR-chromatin interactions? These and other fundamental questions need to be answered in order to understand the full functioning of NHRs as transcription factors. In part, the answers are still missing because little is known about significant aspects of NHR structure, knowledge that is needed to provide the basis for critical specific interactions with other transcription factors. The remainder of this chapter outlines briefly the structural information available for the three major domains found in the NHRs.
NTD
Although detailed structural information is available for several NHR individual domains, expressed as recombinant peptides, no structure of a full-length NHR or of an NTD has been published. In terms of sequence homology, the NTDs are the most poorly conserved regions within the family. NTDs are of widely varying size and sequence. They are often involved in transcriptional regulation within specific cell types. In many NHRs this domain is highly immunogenic, suggesting that it is open to aqueous solvents, and it contains several known phosphorylation sites. One or more powerful transactivation regions are located within the longer NTDs, which, when combined with a DBD in the absence of LBD, can act constitutively (without a ligand) to activate transcription from genes preceded by the proper response element.
In some members of the NHR family, the NTD contains a major transactivation domain (AF1), and some NHRs have two or three AF regions in the NTD. When AF1 domains have been expressed independently as recombinant peptides, they have shown little specific structure, existing as very large collections of conformers that together register as a random coil. Consequently, until recently, experiments attempting to utilize the single-domain expression approach to obtain structural information of the AF1 domain have not been successful. Predictive algorithms for secondary structure suggest that certain AF1s have the capacity to form limited regions of ␣-helix. At least in the case of glucocorticoid receptor (GR), it has been reported that in the presence of the strong ␣-helix-promoting agent trifluoroethanol, recombinant AF1 peptide acquires helical segments [2] . Independent experiments showed that helixbreaking double proline substitutions in the potential helical regions interfered with the transactivation function of holo GR containing them. However, due to the high diversity in the length and amino acid sequence of the NTDs, there is as yet no general rule that predicts the structure of all of them.
Other data suggested weak AF1 interactions with certain other proteins relevant to transcription initiation [3] . It is generally presumed that AF1 must bind, directly or via co-activators/co-repressors, to some part(s) of the primary transcription machinery. In the absence of data for a three-dimensional structure of the NTD, several theories have been advanced to explain this. Based on observations that negatively charged areas are important for the transactivation function in the case of some transcription factors, it was proposed that, without having any definite structure, AF1 acts by providing a cloud of negatively charged amino acids. However, mutational analysis of the GR suggests that this is not the case. Perhaps more intellectually satisfying are suggestions that an induced conformation or set of conformations occurs in AF1 in order for it to carry out its transcription function. This kind of induced fit has been reported in otherwise unstructured activation domains of some transcription factors ( [4] and references therein). The question is, what causes these conformations? Induced fit could occur when the AF1 domain encounters its proper binding partner(s), or AF1 could exist as an equilibrium between a large proportion of unstructured forms and a small proportion of forms properly structured for functional protein-protein interactions. In the latter case, shifting the equilibrium towards properly structured AF1 conformer(s) would favour binding to the co-regulatory proteins. Alternatively, by the induced-fit model, initial non-specific AF1-co-regulator interactions could result in AF1 becoming properly folded as a heteromeric complex with the protein-binding partner. The alternatives are thermodynamically equivalent [5] .
The question for the equilibrium model is what conditions might cause AF1 to acquire the correct conformation? Recent data on the NTD AFs of the GR, androgen receptor (AR), progesterone receptor (PR) and oestrogen receptor (ER) indicate that inter-and intra-molecular forces could be responsible for AF reaching the desired conformation ( [5] [6] [7] and references therein). Exposing purified recombinant AF1 protein to the osmolyte trimethylamine N-oxide (TMAO) results in the domain folding co-operatively into a three-dimensional structure [5, 6] . Osmolytes are naturally occurring small compounds that protect proteins in their naturally folded and functional states, and favour such folding from the denatured state due to their solvophobic effects on the peptide backbone ( [7] and references therein). The protein backbone comprises the most numerous functional groups in proteins, hence osmolyte-induced conformations are driven by very strong forces, and evidence from several systems studied thus far indicates that native folded functional protein species result ( [7] and references therein). Well-known cellular osmolytes include TMAO, glycerol, sorbitol, arabitol, glycine, alanine, proline, betaine and sucrose. They may be found at quite high concentrations in some organisms and organs.
However the physical and functional contacts between AF1 and specific co-regulatory proteins are attained, conditional folding of AF1 appears to be important for these interactions. To give a specific example, the folded AF1 domain of the GR should bind a limited set of specific partners, such as cAMP-response-element-binding protein (CREB)-binding protein (CBP), Ada2 and TATA-box-binding protein (TBP). Weak GR AF1 binding to these was demonstrated in the absence of osmolytes, consistent with the equilibrium. In the presence of the osmolyte TMAO, the interactions are significantly increased, and additionally binding of steroid receptor co-activator 1 (SRC-1) was observed [5] . These findings are consistent with the osmolyte shifting the equilibrium between unstructured and structured AF1 states in favour of the latter, which can then interact efficiently with other binding partners. Similar results have been obtained for the AR [6] . This possibility will become clearer when the three-dimensional structures of some AF1s become available. One interesting point will be to see whether the various AF1s, which differ so considerably in primary sequence, differ or share similarities in three-dimensional structure.
The NTD contains several regions at which post-translational modifications occur. A number of amino acids in the NTD are found to be phosphorylated to varying extents in NHRs isolated from cells or tissues. The effects of site-specific phosphorylations in the NTD on their transcription activating functions vary with particular NHRs [8] . The effects of NTD phosphorylation on AF1 folding have not been investigated in depth. Another important modification of NHR NTDs is sumoylation. At least some NHRs have the SUMO (small ubiquitin-related modifier) peptide added to a lysine residue in their NTDs, at a position between AF1 and the DBD. The effect on structure is unknown, but sumoylation may affect transcriptional transactivation efficiency and possibly nuclear localization [9] . In summary, although as yet no unified structure of an NHR NTD is known, a plausible functional model has been developed. The activation function regions of the NTDs seem to be among the large fraction of protein domains that are natively unfolded ( [7] and references therein). The NTD AFs probably undergo conditional folding under the influences of DNA binding by the DBD, AF interactions with coactivators, co-repressors and other proteins or other NHR domains, and possibly the intracellular concentrations of osmolytes.
DBD
Structurally and with respect to primary sequence, the DBD is the most conserved region among the members of NHR superfamily. It contains eight highly conserved cysteine residues, found in two groups of four. Each group is involved in the tetrahedral co-ordination of a single Zn atom. Although these groupings are often referred to casually as zinc fingers, they do not form the three-dimensional structures seen in classic zinc-finger proteins. The threedimensional structures of the DBD of several NHR members have been solved and discussed extensively ( [4] and references therein); therefore only a brief description will be given here. The data from recombinant DBDs indicate that this domain is folded into a globular shape, containing two helices perpendicular to one another, forming the base of a hydrophobic core. One helix is involved in site-specific DNA binding due to its interaction with certain bases in the major DNA groove of its cognate hormone-response element (HRE). Three or four amino acids within this helix are responsible for the site-specific discrimination of binding. The DBD binds to DNA sequences in the HRE as a dimer, with one subunit binding to the HRE specifically and other one non-specifically. The basic building block of these HREs is a receptor-type-specific five-or six-nucleotide sequence comprising a 'half-site'. The classic HRE is composed of a pair of these pentamers/hexamers. The number of non-specific nucleotides providing spacing between them, and their orientation to one another (direct or inverted repeats), makes for a considerable degree of receptor-binding specificity. For some NHRs the DBD-HRE binding is co-operative, with the first specific interaction followed by a sharp increase in affinity as a second DBD monomer is added. Other NHRs, e.g. the ER, appear to dimerize prior to HRE binding. For the steroid NHR subclass, the loop formed between the first two cysteine residues of the second zinc finger provides the dimerization surface. These NHRs dimerize 'head to head' and the base sequences of their HREs are appropriately palindromic. Other classes of NHRs make heterodimers at their HREs. Both the HREs and the protein dimers are head to tail. Prime examples are the thyroid receptor and retinoid receptors, in which the retinoid X receptor heterodimerizes with a thyroid receptor or a retinoid A receptor [10] .
The standard model of NHR-DNA binding holds that the effect of the high-affinity binding of receptor to its cognate HRE is to tether the receptor at relevant sites on the genome. Recent data suggest that site-specific DNA binding is a more active event. Site-specific binding of a two-domain recombinant GR to a glucocorticoid response element led to intramolecular signalling in the receptor, causing a conformational change in its AF1 domain [11] . Intramolecular signalling upon site-specific DNA binding also has been shown with the PR. When a two-domain form of the progesterone receptor (NTD+DBD) is expressed, some structure exists in its AF1 domain. DNA binding, however, stabilizes the structure of the region N-terminal to the DBD [12] . Together, these results with two NHRs support the hypothesis that binding to an HRE is not simply a tethering event, as traditional models have held, but a step that initiates intramolecular signals, leading to formation of additional structure in AF1 and other parts of the NTD.
LBD
With respect to amino acid sequence, the LBD is the second most conserved domain of the NHRs, and it is known to participate in several actions of NHRs. The solved three-dimensional structures of several LBDs show great similarity. This domain contains the site for ligand binding, is involved in homo-and/or hetero-dimerization, and transcriptional activation ( [4] and references therein). Ligand binding brings conformational changes in the receptor that controls the above-mentioned properties and thus influences gene regulation. Although no extensive evidence is available as to whether these ligand-dependent conformational changes in the LBD cause alterations in other domains, it seems likely that they are affected as well. From crystal structural data on the LBDs of several NHRs, it has been shown that this domain consists of about 12 helices folded into a globular structure. Three sets of helices form the sides and top of the globule, making a central pocket, the ligand-binding site. This overall folding appears to be universally conserved among the NHRs, though as would be expected, the exact dimensions of the pocket vary to suit the ligand(s) specific for each class of NHR ( [4] and references therein). Molecular genetics had shown that near the C-terminus of the LBD of several of these hormone-binding receptors lies a short amino acid sequence, known as AF2, important for activating gene transcription ( [4] and references therein). Although small, the AF2 transactivation subdomain is very important for the transactivation activity of the NHRs. AF2 binds a number of co-activator and co-repressor proteins via their Leu-Xaa-Xaa-Leu-Leu motifs, and, as mentioned above, these proteins apparently act as molecular bridges between the receptor and the fundamental transcription-initiation complex of proteins. Several co-activators and co-repressors also carry out important enzymic modifications of chromatin [13] .
The most C-terminal helix (usually H12) contains the sequence critical to the AF2 transcription-activating function, as it affects the LBD surface upon which much co-activator/co-repressor binding depends. H12 is believed to change position upon ligand binding, flipping from an 'open' position to one closed over the bound ligand. The result is that the LBD now presents a surface favourable for binding the co-activators or co-repressors. At least some ligands that act as antagonists appear to cause altered movement of H12 to a position that creates an unfavourable surface for co-activator binding [14] . However, some steroid hormones, originally identified as antagonists in test systems, are now known to act as agonists in certain tissues. Several possible explanations are offered for the paradox stemming from these indisputable results. In general, it is thought that the large complex of proteins that assembles with the receptor at its AF1 and AF2 sites varies between tissues. Thus, while the fold caused by a given ligand may present binding of a key co-activator in one tissue (antagonist action), in a different tissue, that fold may allow binding of a different but equally effective co-activator (agonist action). When one adds the possibilities of effects due to NHR interactions with other transcription factors at their (non-NHR) binding sites, and the connections with other signal transduction pathways, many hypothetical schemes present themselves. Regardless of mechanism(s), the empirical fact that ligands may be agonists in one tissue and antagonists in another has caused great excitement, as scientists seek to create ligands with desirable tissue-specific therapeutic effects. Undoubtedly, as more becomes known about the details of each individual receptor and its associated protein complexes, features important for unique ligand-and tissue-specific functions will make themselves clear.
The structural dynamics of the LBD and its AF2 also provide a reasonable hypothetical explanation for the fact that some NHRs seem transcriptionally active without need for a ligand. It may be that such NHRs, e.g. NURR1 (NUR-related factor 1) [15] , contain an 'LBD' that inherently folds so as to present a favourable surface for co-activator binding. Orphan receptors often have very small NTDs and thus may rely for function largely on the AF activity found in their 'LBDs'. Other known behaviours of NHRs can be understood in terms of the functional structures of their LBDs. The steroid-binding group of NHRs can be activated in vitro without ligand by exposure to high salt concentrations and/or mild heating. This may well be due to such conditions causing AF2 to fold in a conformation favourable for binding co-activators. The retinoid/thyroid receptors are thought to be able to bind their response elements and attract co-repressors in the absence of ligands. Specific ligand binding shifts the position of H12, altering the cofactorbinding surface so as to favour co-activator binding. Thus the receptor shifts from a gene-repressing to a gene-activating function.
NHRs and co-regulatory proteins
It is well established that certain specific co-regulatory proteins interact with members of the NHR superfamily. Various co-regulators are either required for or enhance the NHR effect on target gene transcription. These interactions lead to stabilization of NHRs and the basal transcription machinery at the promoter, and to covalent modification of histones, which presumably facilitates or inhibits entry of the transcription complex of proteins to the DNA. Thus these co-regulatory proteins appear to function by either remodelling chromatin structure and/or acting as adapter molecules between NHR and components of the basal transcriptional apparatus. Studies from several laboratories have led to the identification of a series of nuclearreceptor-interacting co-regulatory proteins ( [13] and references therein). Most of these are reported to interact with either the AF1 or the AF2 domain, or both. A few other proteins, such as c-Jun, nuclear factor B, GT198 and some signal tranducers and activators of transcription (STATs) interact with the DBD. Other proteins are recruited to the co-regulators that bind the NHR directly, so that a large NHR-co-regulator complex is assembled. Two classes of co-activator complex are recruited either simultaneously or combinatorially. One set promotes the nucleosomal remodelling required for transcriptional activation or repression, and another one forms a direct bridge to the transcriptional machinery apparatus. The structural nature of these large molecular complexes remains a challenge for the future.
Although in most experimental systems either AF1 or AF2 alone is capable of regulating transcription to some extent, full transcriptional activation by NHRs usually requires functional synergy between the two transactivation function regions ( [7] and references therein). Recent data show that for the GR at least, the nature of the DNA template is critical to the effect seen. For induction from a promoter in a natural chromatin background, AF1 was quantitatively more important than AF2 [16] . In a natural holoreceptor it is likely that a physical intramolecular association occurs between the NTD and the LBD. This has been supported by studies with the PR-B isoform, in which a ligand-dependent, direct interaction between the N-terminal and C-terminal domains has been shown [17] . Such an interaction takes place only when an agonist is bound, and antagonist binding prevents it, suggesting a conformational change in the agonistbound LBD that suits it for this interaction. Furthermore, ubiquitous co-activators such as SRC-1 and p300/CBP are not required for this physical association; thus it seems that the LBD-NTD interaction may be a direct one. AR NTD and LBD interactions are also well documented [18] .
Bridging proteins between the two NHR domains may come into play in some circumstances. It has been reported that through different regions, SRC-1 is able to interact with both the AF1 and AF2 regions of several steroid receptors. Co-operativity observed between AF1 and AF2 regions appears to be assisted as well by other cofactor proteins, such as TIF2 [19] . Another co-acti-vator complex, DRIP/TRAP (vitamin D receptor-interacting protein/thyroid receptor/associated protein), also has been reported to interact with both AF1 and AF2 regions in several NHRs [20] . Observations of synergism between AF1 and AF2 are also observed involving p300/CBP and the ER [21] . One report indicates that SRC-1 interaction with the AF1 region of the ER requires the putative ␣-helical core of the AF1 region [22] , consistent with results from the GR AF1, where it has been shown that conditional folding of the AF1 domain is a prerequisite for its interaction with SRC-1 [5] .
Conclusions
In the certainty that protein function depends on structure, studies of NHR structure have been pursued vigorously in recent years. Up to the present, these studies have utilized recombinant proteins representing portions of the holoreceptors. Recombinant proteins encompassing the DBDs and/or LBDs of several NHRs have been shown to fold into globular forms, allowing their structures to be determined. In conjunction with a vast amount of other experimentation in many laboratories, these structures have greatly aided our understanding of how the NHRs interact with their specific DNA-binding sites, dimerize with one another, and respond to the binding of specific ligands. The NTDs of the NHRs have been more difficult to study structurally, because when they are exposed as recombinant proteins they show little structure. Recently, however, methods have been developed that cause NTDs to assume three-dimensional structures, suggesting that these will become more accessible for study.
Analyses short of full structural determinations on recombinant proteins containing two NHR domains have begun to appear. Early data from these suggest that site-specific DNA binding results in acquisition of significant structure in the attached NTD. This is consistent with hints from molecular biological experiments suggesting that particular sequences within DNA-binding sites for NHRs may affect NHR functions. NHRs also affect transcription through protein-protein interactions at non-cognate DNA sites. The structural basis for this type of control over transcription is obscure.
Structures of holo NHRs have yet to be achieved, and for full understanding of their actions, these structures will be necessary. Indeed, well beyond that, we will need to discover the structures of the large, multiprotein complexes that are obviously critical to NHR function.
Summary

• NHRs are multi-domain proteins that function as transcription factors.
• NHR family members share identity owing to the structural similarity of their DBDs.
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